Ardelyx, Inc. (NASDAQ:ARDX) Forecasted to Earn Q2 2025 Earnings of $0.08 Per Share

Ardelyx, Inc. (NASDAQ:ARDX) – Wedbush increased their Q2 2025 earnings estimates for shares of Ardelyx in a report released on Thursday, May 2nd. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings of $0.08 per share for the quarter, up from their previous estimate of $0.05. Wedbush currently has a “Outperform” rating and a $15.00 price target on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.44) per share. Wedbush also issued estimates for Ardelyx’s Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.17 EPS, FY2025 earnings at $0.37 EPS, FY2026 earnings at $1.01 EPS, FY2027 earnings at $1.44 EPS and FY2028 earnings at $1.87 EPS.

Ardelyx (NASDAQ:ARDX) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $46.00 million during the quarter, compared to analysts’ expectations of $36.40 million. Ardelyx had a negative return on equity of 41.65% and a negative net margin of 41.36%. The business’s revenue was up 303.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.13) earnings per share.

A number of other brokerages have also recently issued reports on ARDX. StockNews.com cut shares of Ardelyx from a “hold” rating to a “sell” rating in a research report on Monday, February 26th. Citigroup boosted their price objective on shares of Ardelyx from $13.00 to $14.00 and gave the company a “buy” rating in a report on Friday, May 3rd. Raymond James raised their target price on shares of Ardelyx from $12.00 to $15.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 9th. Piper Sandler boosted their price target on Ardelyx from $12.00 to $15.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Finally, SVB Leerink initiated coverage on Ardelyx in a research report on Friday, April 5th. They set an “outperform” rating and a $14.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.81.

Ardelyx Stock Performance

NASDAQ:ARDX opened at $9.31 on Monday. The company has a current ratio of 4.53, a quick ratio of 4.36 and a debt-to-equity ratio of 0.66. The stock has a 50 day simple moving average of $7.66 and a 200 day simple moving average of $6.91. Ardelyx has a 1-year low of $3.16 and a 1-year high of $10.13. The stock has a market cap of $2.18 billion, a P/E ratio of -33.25 and a beta of 0.87.

Insider Buying and Selling at Ardelyx

In other Ardelyx news, CEO Michael Raab sold 22,917 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $8.75, for a total value of $200,523.75. Following the sale, the chief executive officer now owns 1,319,951 shares of the company’s stock, valued at approximately $11,549,571.25. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Ardelyx news, CEO Michael Raab sold 22,917 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $8.75, for a total transaction of $200,523.75. Following the completion of the transaction, the chief executive officer now owns 1,319,951 shares of the company’s stock, valued at $11,549,571.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Elizabeth A. Grammer sold 86,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $7.73, for a total transaction of $664,780.00. Following the completion of the sale, the insider now owns 312,993 shares in the company, valued at $2,419,435.89. The disclosure for this sale can be found here. Insiders sold a total of 218,769 shares of company stock worth $1,734,099 over the last three months. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Ardelyx

Hedge funds and other institutional investors have recently modified their holdings of the stock. HighMark Wealth Management LLC acquired a new stake in shares of Ardelyx during the 1st quarter valued at $36,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of Ardelyx during the first quarter valued at about $64,000. SJS Investment Consulting Inc. bought a new stake in shares of Ardelyx during the fourth quarter worth about $62,000. Jump Financial LLC acquired a new position in shares of Ardelyx in the fourth quarter valued at approximately $63,000. Finally, Vontobel Holding Ltd. bought a new position in Ardelyx in the 4th quarter valued at approximately $74,000. Institutional investors own 58.92% of the company’s stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.